Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108669368> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2108669368 endingPage "263" @default.
- W2108669368 startingPage "260" @default.
- W2108669368 abstract "The new standard of care for treatment for infection with genotype 1a/b of HCV now is the combination of telaprevir (TLV) with ribavirin (RBV) and pegylated interferon (Peg-IFN). Although this new therapy gives a higher response rate than the Peg-IFNα plus RBV treatment, a greatly higher rate of anaemia onset has been reported in all clinical trials. Because haemolysis is a typical concentration-dependent side effect of RBV, modulated by ITPA gene polymorphisms, we aimed to compare the early RBV plasma exposure of nine patients after 2 weeks of treatment with triple therapy with RBV concentrations of 187 patients treated with RBV and Peg-IFNα over the same time scale; this comparison was performed also stratifying patients according to ITPA polymorphism genotype and anaemia onset after 1 month of treatment. All TLV-treated patients had unfavourable ITPA genetic profile and developed anaemia. Moreover, both the rate of anaemia onset and the haemoglobin loss at 1 month were significantly higher in patients treated with TLV. This observation has been confirmed also in patients with the same ITPA genetic profile in double therapy. Strikingly, also early RBV plasma concentrations were significantly higher in patients treated with TLV. These unbiased results confirm the observations recently reported and suggest that the high rate of anaemia onset could be mainly due to the increased RBV exposure, probably caused by a ‘boosting effect’ by TLV. These data highlight the great importance of early therapeutic drug monitoring of RBV in the management of anaemia in the triple therapy." @default.
- W2108669368 created "2016-06-24" @default.
- W2108669368 creator A5020133322 @default.
- W2108669368 creator A5021206943 @default.
- W2108669368 creator A5046854142 @default.
- W2108669368 creator A5050025219 @default.
- W2108669368 creator A5076836884 @default.
- W2108669368 creator A5079779731 @default.
- W2108669368 date "2013-09-02" @default.
- W2108669368 modified "2023-10-17" @default.
- W2108669368 title "Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir" @default.
- W2108669368 cites W1979174109 @default.
- W2108669368 cites W1997755547 @default.
- W2108669368 cites W2092710527 @default.
- W2108669368 cites W2122153421 @default.
- W2108669368 cites W2125963799 @default.
- W2108669368 cites W2334943495 @default.
- W2108669368 doi "https://doi.org/10.1111/jvh.12170" @default.
- W2108669368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24597694" @default.
- W2108669368 hasPublicationYear "2013" @default.
- W2108669368 type Work @default.
- W2108669368 sameAs 2108669368 @default.
- W2108669368 citedByCount "23" @default.
- W2108669368 countsByYear W21086693682014 @default.
- W2108669368 countsByYear W21086693682015 @default.
- W2108669368 countsByYear W21086693682016 @default.
- W2108669368 countsByYear W21086693682017 @default.
- W2108669368 countsByYear W21086693682018 @default.
- W2108669368 crossrefType "journal-article" @default.
- W2108669368 hasAuthorship W2108669368A5020133322 @default.
- W2108669368 hasAuthorship W2108669368A5021206943 @default.
- W2108669368 hasAuthorship W2108669368A5046854142 @default.
- W2108669368 hasAuthorship W2108669368A5050025219 @default.
- W2108669368 hasAuthorship W2108669368A5076836884 @default.
- W2108669368 hasAuthorship W2108669368A5079779731 @default.
- W2108669368 hasConcept C126322002 @default.
- W2108669368 hasConcept C203014093 @default.
- W2108669368 hasConcept C2522874641 @default.
- W2108669368 hasConcept C2776408679 @default.
- W2108669368 hasConcept C2776461080 @default.
- W2108669368 hasConcept C2778159067 @default.
- W2108669368 hasConcept C2778248108 @default.
- W2108669368 hasConcept C2779300928 @default.
- W2108669368 hasConcept C2780040827 @default.
- W2108669368 hasConcept C71924100 @default.
- W2108669368 hasConcept C90924648 @default.
- W2108669368 hasConceptScore W2108669368C126322002 @default.
- W2108669368 hasConceptScore W2108669368C203014093 @default.
- W2108669368 hasConceptScore W2108669368C2522874641 @default.
- W2108669368 hasConceptScore W2108669368C2776408679 @default.
- W2108669368 hasConceptScore W2108669368C2776461080 @default.
- W2108669368 hasConceptScore W2108669368C2778159067 @default.
- W2108669368 hasConceptScore W2108669368C2778248108 @default.
- W2108669368 hasConceptScore W2108669368C2779300928 @default.
- W2108669368 hasConceptScore W2108669368C2780040827 @default.
- W2108669368 hasConceptScore W2108669368C71924100 @default.
- W2108669368 hasConceptScore W2108669368C90924648 @default.
- W2108669368 hasIssue "4" @default.
- W2108669368 hasLocation W21086693681 @default.
- W2108669368 hasLocation W21086693682 @default.
- W2108669368 hasOpenAccess W2108669368 @default.
- W2108669368 hasPrimaryLocation W21086693681 @default.
- W2108669368 hasRelatedWork W1558399493 @default.
- W2108669368 hasRelatedWork W1967751250 @default.
- W2108669368 hasRelatedWork W1978588902 @default.
- W2108669368 hasRelatedWork W2001193545 @default.
- W2108669368 hasRelatedWork W2013740604 @default.
- W2108669368 hasRelatedWork W2043906981 @default.
- W2108669368 hasRelatedWork W2108669368 @default.
- W2108669368 hasRelatedWork W2116848809 @default.
- W2108669368 hasRelatedWork W2162668946 @default.
- W2108669368 hasRelatedWork W2315426868 @default.
- W2108669368 hasVolume "21" @default.
- W2108669368 isParatext "false" @default.
- W2108669368 isRetracted "false" @default.
- W2108669368 magId "2108669368" @default.
- W2108669368 workType "article" @default.